Cosponsor the Sickle Cell Disease Comprehensive Care Act – Hematology.org
Cosponsor the Sickle Cell Disease Comprehensive Care Act
Cosponsor the Sickle Cell Disease Comprehensive Care Act
Thrombin activatable fibrinolysis inhibitor (TAFI) is one of the most important physiological fibrinolysis inhibitors. Its inhibitory efficacy under physiological condition remains uncertain.
Lupus anticoagulant (LA) represents 1 of the laboratory criteria for classification of patients as having definite antiphospholipid syndrome (APS). The other 2 laboratory criteria are…
Research shows diversity in cancer providers improves access to care and satisfaction with care. Diversity among providers also improves health outcomes. But diversity in a…
October 11-12, 2024
Phobias can make cancer treatment even more challenging for patients. Ahead, psychiatrist Erica Taylor, M.D., shares advice for those struggling with treatment-related phobias such as…
The XIX International Symposium on Amyloidosis (ISA) will be held in Rochester, MN, between May 26-30, 2024. This meeting will cover a variety of amyloidosis…
Medscape is pleased to present several live symposia in Chicago, Illinois, in June 2024. These in-person and virtual events feature expert panelists who will guide…
The JCO Journals Lounge is a place where anyone can gather to relax, take a coffee break, and/or network. Check the schedule below for events…
Beta-blocker therapy did not reduce negative intrusive thoughts or anxiety among cancer survivors, according to results of an emulated trials analysis published in BMC Cancer.…
Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.